Grand Rounds Lecture

See the full schedule at cancer.northwestern.edu/grandrounds

  1. Developing a Phase I Clinical Trial of R-CHOP Plus SYK Inhibitor TAK-695 for the Front-Line Treatment of High-Risk Diffuse Large B Cell Lymphoma

    Craig Boddy, MD
    Fellow, Division of Hematology/Oncology
    Northwestern University, Feinberg School of Medicine
    Chicago, IL

  2. PI3K Inhibition in Trastuzumab Resistant HER2-Positive Breast Cancer

    Ami Shah, MD
    Fellow, Division of Hematology/Oncology
    Northwestern University, Feinberg School of Medicine
    Chicago, IL

+ Add to your calendar

Supported by the Lurie Cancer Center and the Division of Hematology/Oncology

Accreditation Statement
The Northwestern University Feinberg School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
The Northwestern University Feinberg School of Medicine designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.